We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

MedXY Editorial Team•Aug 11, 2026•news
Cost-EffectivenessimmunotherapypembrolizumabPD-L1head and neck cancer

Highlight

  • KEYNOTE-689 trial showed perioperative pembrolizumab enhances event-free survival in locally advanced head and neck squamous cell carcinoma (HNSCC).
  • Cost-effectiveness analysis reveals pembrolizumab is economically viable only in patients with PD-L1 combined positive score (CPS) greater than 10.
  • Subgroup with CPS 1 to 10 exhibits marginal health gains at high incremental costs, limiting economic justification.
  • Biomarker-driven stratification can guide value-based use of immunotherapy in HNSCC treatment protocols.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

EHR-Integrated Synoptic Operative Reporting: Enhancing Documentation in Head and Neck Oncologic SurgeryThis study evaluates the development, implementation, and performance of EHR-integrated synoptic operative reporting templates in head and neck cancer surgery, highlighting improved documentation quality and variable adherence.Sep 27, 2026Cost-Effectiveness of Thoracentesis with Pleural Fluid Cytology Versus Thoracoscopy with Pleural Biopsy in Diagnosing Malignant Pleural EffusionThis study evaluates when thoracentesis or thoracoscopy is more cost-effective in diagnosing malignant pleural effusion in patients with prior or active malignancy, highlighting thresholds of pleural fluid cytology sensitivity guiding optimSep 24, 2026Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness AnalysisThis review synthesizes evidence on the cost-effectiveness of standalone salpingectomy for ovarian cancer prevention, highlighting its benefits primarily in women at moderately elevated risk, especially between ages 45-50, supporting tailorSep 23, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell Carcinoma
This study reveals coordinated cellular programs underlying response and resistance to neoadjuvant PD-L1 blockade in ESCC, highlighting potential combinatorial immunotherapy targets for personalized treatment strategies.
Sep 22, 2026
Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior StudiesDapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.Sep 22, 2026
Robotic Versus Laparoscopic Cholecystectomy: Balancing Safety, Efficacy, and Cost with a Novel Risk CalculatorThis study compares robotic and laparoscopic cholecystectomy, highlighting robotic surgery’s advantages in safety for high-risk and obese patients despite higher costs, and introduces a predictive risk calculator to aid surgical decisSep 21, 2026